SCHEMBL1869301

SCHEMBL1869301

COc1cc2nc(Nc3ccc(S(N)(=O)=O)cc3)ncc2cc1C#Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.45
IKBKB O14920 5/20 0.45
STK4 Q13043 1/20 0.45
CA2 P00918 6/20 0.44
CA1 P00915 5/20 0.44
CA9 Q16790 5/20 0.44
CA12 O43570 3/20 0.44
EGFR P00533 1/20 0.43
KDR P35968 1/20 0.43
BMPR2 Q13873 3/20 0.43
CDK2 P24941 2/20 0.42
CCNA2 P20248 1/20 0.42
CDK1 P06493 1/20 0.41
CDK4 P11802 1/20 0.41
CCNB1 P14635 1/20 0.41
CCND1 P24385 1/20 0.41
CCNE1 P24864 1/20 0.41
PLK1 P53350 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1871929 0.85 CA2 (0.49) PDE5AIKBKBSTK4CA2CA1
SCHEMBL1571331 0.84 PDE5A (0.57) PDE5AIKBKBSTK4CA2CA1
SCHEMBL3504058 0.83 IKBKB (0.47) IKBKBSTK4CA2CA1CA9
SCHEMBL1571344 0.81 IKBKB (0.54) PDE5AIKBKBSTK4CA2CA1
SCHEMBL13362948 0.77 PDE5A (0.52) PDE5AIKBKBSTK4CA2CA1
SCHEMBL1868004 0.76 IKBKB (0.45) IKBKBSTK4CA2CA1CA9
SCHEMBL1633099 0.74 IKBKB (0.65) IKBKBSTK4CA2CA1CA9
SCHEMBL13251989 0.74 BRAF (0.53) IKBKBSTK4CA2CA1CA9
SCHEMBL3503813 0.74 BMPR2 (0.44) IKBKBSTK4CA2CA1CA9
SCHEMBL13251853 0.73 CA2 (0.51) IKBKBCA2CA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008079988-A9 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS AG (CH) 2011-05-12 WO claimed
US-20100216767-A1 QUINAZOLINES FOR PDK1 INHIBITION AIKAWA MINA 2010-08-26 US claimed
US-20100216767-A1 QUINAZOLINES FOR PDK1 INHIBITION AIKAWA MINA 2010-08-26 US disclosed
US-20100216767-A1 QUINAZOLINES FOR PDK1 INHIBITION AIKAWA MINA 2010-08-26 US disclosed
US-20100121052-A1 Novel compounds for treating proliferative diseases JAIN RAMA 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216767-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 PDE5A 1105/4885IKBKB 1011/4885STK4 78/4885
US-20100121052-A1 Novel compounds for treating proliferative diseases PDK1, PDK2, PDK3 PDE5A 1771/4885IKBKB 942/4885STK4 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.